InoLife Technologies, Inc. (INOL) released today the strategic joint venture agreement with Gulf Coast Pharmaceuticals, Inc. for distribution and sales of its DNA-based products.
“Our agreement with Gulf Coast Pharmaceuticals provides InoLife Technologies, Inc. with a vital sales channel and vast product outreach to our key customers, including consumers, hospitals, general practitioners and cardiologists,” said Gary Berthold , President, CEO of InoLife Technologies, Inc. ” Gulf Coast will provide our company with a large-scale distribution warehouse and a North American-wide sales force, allowing us to accelerate market penetration of our DNA-based product line.”
Gulf Coast’s primary product sales and distribution focus will be InoLife Technologies, Inc.’s Genetic Predisposition Test. This unique product is designed to recognize an individual’s DNA and identify key markers that, if present, may cause a person to develop serious diseases prematurely. DNA testing reveals genetic predispositions for 25 diseases and conditions in five major categories. Gulf Coast will also distribute InoLife Technologies, Inc.’s Cytochrome CYP2C19drug metabolism analysis; a test that determines if a patient has a genetic variation that may reduce the effectiveness of Plavix. If that patient has the genetic variation, the risk of having a stroke, heart attack or other serious cardiac event is higher.
“We are extremely proud to have been selected by InoLife as its strategic venture partner,” said Ken Ritchey , President and CEO of Gulf Coast . “We are in a unique position because we have an existing sales force and nationwide pharmaceutical and medical supply distribution network that parallels Inolife Technologies, Inc.’s core target markets, especially since their DNA-based products must be prescribed and interpreted by a physician.”